Latest News - Shire

Wednesday, March 22, 2017 | Management/Leadership, Shire

Joe Boyd Joins Shire as Director, Market Development, Ophthalmics

Shire has announced that Joe Boyd has joined the Ophthalmics team as Director, Market Development. In this role, Mr. Boyd will work closely with thought leaders, key opinion leaders, and teaching inst…

Read the full story

Friday, February 17, 2017 | Dry Eye, Earnings & Financials, Shire

Shire Provides Update on Early Xiidra Sales

As part of its fourth quarter and full-year earnings release on Thursday, Shire provided information about the early sales of its dry eye disease drug Xiidra (lifitegrast), which was launched in Augus…

Read the full story

Monday, January 30, 2017 | Management/Leadership, Shire

Shire Names Sushanta Mallick as VP, Global Development Lead for Ophthalmics

Shire has named Sushanta Mallick to its ophthalmics team as vice president and global development lead for clinical development, ophthalmics, according to a company announcement. Mr. Mallick, a former…

Read the full story

Tuesday, January 17, 2017 | Management/Leadership, Shire

Sushanta Mallick Joins Shire Ophthalmic as VP & Global Development Lead for Clinical Development

Shire has annoucned that Sushanta Mallick has joined the ophthalmics team as Vice President & Global Development Lead for Clinical Development, Ophthalmics. Mr. Mallick has more than 20 years o…

Read the full story

Monday, October 17, 2016 | Medical Studies, Shire

Shire Survey: Modern Technology and a Multi-Screen Lifestyle Viewed as Important Factors in Rising Prevalence of Dry Eye Disease

Shire announced that in results released today from a new national survey, nearly nine in 10 eye care professionals (ECPs) (89%) believe our modern, multi-screen lifestyle (i.e., everyday use of mobil…

Read the full story

Monday, August 29, 2016 | Product Releases, Shire

Shire’s Xiidra (Lifitegrast) Is Now Available by Prescription in the United States

Shire announced that Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily prescription eye drop indicated for the treatment of the signs and symptoms of dry eye disease, is now available by pres…

Read the full story

Thursday, August 25, 2016 | Partnerships, Shire

Shire Partners with Jennifer Aniston to Raise Awareness of Dry Eye; Launches eyelove Campaign

Jennifer Aniston is one of the millions of Americans who experience symptoms consistent with chronic dry eye. In partnership with Shire, Ms. Aniston is encouraging people to make eye health a priority…

Read the full story

Tuesday, July 26, 2016 | Dry Eye, Shire

Shire Prices Xiidra at $5K per year - Right on Par with Restasis

Dublin-based Shire has decided to roll out its new product - green-lighted by the FDA earlier this month - at about $5,000 per year, according to Evercore ISI analyst Umer Raffat. A 30-day supply will…

Read the full story

Friday, July 22, 2016 | Management/Leadership, Shire

Beth Marsh Joins Shire's Ophthalmics Team as Commercial Strategy Lead for Infectious Conjunctivitis Drug Candidate

Beth Marsh recently joined Shire's ophthalmics team as Commercial Strategy Lead for SHP640, the development program for a novel agent being investigated to treat infectious conjunctivitis (adenovi…

Read the full story

Tuesday, July 12, 2016 | Dry Eye, Shire

Shire Secures Access to 16 Million-Strong US Dry Eye Disease Market With New Drug Approval

Approximately 16 million US adults diagnosed with dry eye disease will now have access to the first drug specifically indicated for this condition, following FDA approval of Shire’s lifitegrast …

Read the full story

Monday, July 11, 2016 | Dry Eye, FDA Approval/Clearance, Shire

FDA Approves Shire’s Xiidra (Lifitegrast) for the Signs and Symptoms of Dry Eye Disease

In a long-awaited announcement on Monday, Shire confirmed that the FDA has approved its blockbuster dry eye treatment Xiidra (lifitegrast ophthalmic solution 5%), marking the first prescription pharma…

Read the full story

Thursday, June 30, 2016 | Clinical Trials, Shire

Shire Drug Candidate, SHP607, Does Not Meet Primary Endpoint of Reducing the Severity of ROP in Extremely Premature Infants; Reduces Other Morbidities

Shire announced that its phase 2 study evaluating an investigational protein replacement, SHP607, did not meet its primary endpoint of reducing the severity of retinopathy of prematurity (ROP), accord…

Read the full story

Thursday, March 31, 2016 | Management/Leadership, Shire

Shire CEO Ornskov Racks Up $21 Million in Pay, a Fivefold Leap From 2014

Shire CEO Flemming Ornskov took a flying leap into the ranks of pharma's highest paid executives last year. He racked up 2015 pay of $21.6 million--a fivefold increase from 2014's mere $4 mill…

Read the full story

Monday, February 29, 2016 | Management/Leadership, Shire

Shire Ophthalmics Hires Kathy Kobe as Head of US Sales

Shire is continuing to expand its ophthalmics team and has appointed Kathy Kobe as Head of US Sales, Ophthalmics. Ms. Kobe brings more than 24 years of pharmaceutical experience with 10 years focused …

Read the full story

Thursday, February 04, 2016 | Dry Eye, Shire

FDA Acknowledges Receipt of Lifitegrast Resubmission; Begins 6-Month Review Period

Shire announced that the FDA has acknowledged receipt of the resubmission of the new drug application (NDA) for lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. Shire …

Read the full story
Load More